Ningxia Medical University to Transfer Patent for Antidepressant Polysaccharide Lyophilized Powder Derived from Stellaria dichotoma for RMB 40,000
Recently, Ningxia Medical University released a public notice on the transformation of scientific and technological achievements, proposing to“A Polysaccharide Lyophilized Powder with Antidepressant Effects, and Its Preparation Method and Application”The relevant patents have been transferred to Xinjiang Huachun Biological Pharmaceutical Co., Ltd., with a proposed transfer amount of40,000 yuan。
This patent relates to a polysaccharide lyophilized powder with antidepressant effects, as well as its preparation method and applications. The core innovation lies inPreparation of Lyophilized Powder of Polysaccharides Extracted from the Natural Medicinal Herb Radix Bupleuri Stellati, overcoming the industry pain point of significant side effects associated with existing clinical antidepressant Western medications, which often lead to patient discontinuation due to intolerance, throughAqueous extraction and alcohol precipitation, protein removal by resolubilization, concentration and freeze-dryingSilver Bupleurum polysaccharide freeze-dried powder, prepared through an exclusive proprietary process, is natural, safe, and free of serious side effects. Animal experiments have verified its clear and significant antidepressant efficacy. Its mechanism of action involves regulating the levels of monoamine neurotransmitters in the brain and normalizing the negative feedback function of the hypothalamic-pituitary-adrenal (HPA) axis, thereby providing a novel natural product direction for the development of antidepressant drugs.
Depression is one of the most common mental disorders in current clinical medicine. Its clinical manifestations are diverse and complex, with core symptoms characterized by persistent low mood, feelings of inferiority marked by self-denial, anhedonia (loss of pleasure), and a state of hopelessness regarding life. Some patients also present with comorbid symptoms such as anxiety. In severe cases, patients may exhibit suicidal ideation or engage in suicidal behaviors, posing a serious threat to their safety and well-being.
Furthermore, this disease is characterized by significant recurrent episodes and a protracted, refractory course. It imposes long-term and severe psychological and physiological impairments on patients, substantially diminishing their quality of life and exerting numerous adverse effects on their family and social functioning, thereby posing substantial harm to both physical and mental health. With the rapid development of the socio-economy, escalating competitive pressures in daily life have led to an increase in psychological stressors, resulting in a rapidly rising incidence of depression. Consequently, it has become a critical public health issue that urgently requires societal attention and intervention.
In the clinical treatment of depression, due to the complex pathogenesis and high propensity for relapse, patients often require long-term pharmacotherapy, resulting in a relatively prolonged overall treatment course.Sustained Efficacy and Safety of the Drughave become key to treatment. Currently, the antidepressant regimens commonly used in clinical practice are still dominated by synthetic Western medicines, primarily including selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and heterocyclic antidepressants. Although these medications can alleviate depressive symptoms to some extent, they are generally associated with various significant adverse effects that impose an additional burden on patients’ bodies. For instance, they may trigger hypertensive crises, exacerbate hypomanic symptoms, cause decreased libido, and induce serotonin toxicity, leading to a series of discomforts such as mania, agitation, and insomnia.
Clinical survey data indicate that a considerable proportion of patients taking antidepressants are forced to discontinue treatment due to intolerance of the associated side effects. This not only directly compromises the therapeutic efficacy for depression, leading to relapse or even exacerbation of the condition, but also increases the difficulty of subsequent treatment, representing a major challenge in the clinical management of depression.
Against this backdrop, there is an increasingly urgent clinical demand for the development of novel antidepressants with proven efficacy and reduced side effects. How to break through the limitations of existing chemically synthesized drugs, discover and extract active ingredients with potent antidepressant effects from natural products, and develop antidepressants with higher safety and better tolerability to meet the long-term pharmacotherapy needs of patients with depression has become a critical research challenge for professionals in the pharmaceutical field, as well as a core direction driving innovation in the development of antidepressant medications.
This technology for freeze-dried powder of polysaccharides from *Bupleurum scorzonerifolium*, which exhibits antidepressant effects, represents a significant innovation in the field of antidepressant drugs by leveraging the core R&D philosophy of natural products. It offers substantial advantages in terms of raw materials, manufacturing processes, efficacy, and safety, thereby overcoming many limitations associated with conventional western antidepressants.
The core innovation of this technology lies in the first-time application ofStellaria RootThis traditional Chinese medicinal material serves as the core raw material for extracting polysaccharides to prepare an anti-depressant freeze-dried powder. This approach fully leverages the pharmaceutical value of natural herbs, ensuring that the active anti-depressant ingredients are derived from natural sources and safeguarding medication safety at the raw material level. Experimental verification has confirmed that this component is non-toxic and does not cause severe adverse drug reactions, thereby addressing a critical pain point associated with conventional Western antidepressants, which often induce multiple adverse effects in clinical practice.
InPreparation ProcessAbove, the technology was designedWater extraction and alcohol precipitation, sediment collection, protein removal by redissolution, concentration and freeze-dryingThe proprietary preparation process, along with the optimization of process parameters such as the solid-liquid ratio, extraction time, concentration temperature, and centrifugation conditions, has achieved efficient extraction and purification of Stellaria dichotoma polysaccharides. This approach not only increases the yield of polysaccharide precipitation but also ensures the effective content of polysaccharides in the freeze-dried powder. The process steps are scientifically standardized and highly operable, laying a solid foundation for industrial-scale translation.
AtPharmacological EffectsAt the level of, the technology's R&DSilver Bupleurum Polysaccharide Lyophilized Powder Has Clear and Significant Antidepressant Effects, validated through animal experiments, it can effectively improve depression-related behavioral manifestations, andNo additional central excitatory or inhibitory effects, while exerting antidepressant effects, it does not affect the body's spontaneous activity, demonstrating excellent efficacy.
And inMechanism of Actionabove, this technologyAchieved an Innovative Breakthrough in Dual Regulation, Stellaria dichotoma polysaccharides can not only effectively regulate the levels of monoamine neurotransmitters in the brain and restore the normal levels of related neurotransmitters and metabolic enzymes in key brain regions such as the hippocampus and cortex, but also reconstruct the normalized negative feedback function of the HPA axis and reverse the abnormal elevation of glucocorticoids in depression models, fromNeurotransmitter RegulationandEndocrine System RepairIt exerts antidepressant effects through two dimensions, with a clear and comprehensive mechanism of action, providing novel therapeutic targets and research directions for the development of antidepressant drugs.
Furthermore, this technology clearly demonstrates the direct application value of polysaccharides from Stellaria dichotoma var. lanceolata in the development of antidepressant medications. The research outcomes can be directly integrated into industrial-scale pharmaceutical production, providing a novel natural therapeutic option for clinical antidepressant treatment. This advancement fills a gap in the research and development of natural product-derived antidepressants, offering both significant clinical utility and strong potential for industrial translation.
As a natural plant-derived antidepressant, Stellaria dichotoma polysaccharide freeze-dried powder enjoys promising market prospects, driven by evolving market demands, supportive policy orientations, and its inherent technological advantages. With the continuously growing population of patients with depression, there is an increasingly urgent clinical need for antidepressants with low side effects and high safety profiles. The adverse reaction issues associated with traditional chemical drugs have created substantial market space for natural product-based antidepressants, laying a solid foundation for their clinical application and market promotion.
Currently,Modernization of Traditional Chinese MedicineBecoming a Key Driver for the Pharmaceutical Industry,Natural Plant-Derived DrugsWith its characteristics of natural raw materials and medication safety, it aligns with the current trend toward healthier pharmaceutical consumption, making it more likely to receive policy support and market recognition. The freeze-dried powder of polysaccharides from Stellaria dichotoma (Yinchaihu) uses authentic Chinese herbal materials as its source. Its preparation process is mature, its mechanism of action is clear, and its antidepressant efficacy has been experimentally verified. These factors have established its technological and efficacy advantages, providing a solid foundation for industrialization.
Traditional Small-Molecule Antidepressantsare currently the mainstream category in clinical antidepressant treatment, primarily comprisingSelective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic and heterocyclic antidepressantsRelevant patents and industrialization technologies have matured. Selective serotonin reuptake inhibitors (SSRIs), as the mainstream medication, are widely used and highly prevalent in clinical practice, serving as the first-line treatment for depression at present. Although tricyclic and heterocyclic antidepressants have a long history of application, their clinical use is increasingly limited due to adverse reactions. Monoamine oxidase inhibitors (MAOIs) are reserved for special cases only, owing to clear contraindications. Meanwhile, as market demands for drug safety and tolerability continue to rise, the side effects associated with traditional chemical drugs have become a significant constraint on industry development, posing new challenges to the market growth of these medications.
Morinda Officinalis Oligosaccharide Capsules: China’s First Natural Oligosaccharide-Based Antidepressant Traditional Chinese Medicine Classified as a Category 5 New Drug, byBeijing TongrentangAs a benchmark product among natural product-based antidepressants developed and manufactured in China, it features oligosaccharides from Morinda officinalis as its core active ingredient. It exerts antidepressant effects by regulating neurotransmitters in the brain, primarily targeting the treatment of mild to moderate depression. With a high safety profile and low incidence of side effects, it is suitable for special populations with restrictions on conventional chemical drug use, such as adolescents and postpartum women, as well as for general patients who have low tolerance for the side effects of conventional antidepressants. In terms of market application, the drug enjoys high clinical recognition, has been included in multiple guidelines and expert consensus statements on the diagnosis and treatment of depression, and is widely used in psychiatric departments, traditional Chinese medicine departments, and maternal and child health hospitals. It can be administered as monotherapy or in combination with conventional chemical drugs.
The prevalence of depression continues to rise, creating an increasingly urgent clinical demand for antidepressants with low side effects and high safety profiles. The adverse reaction profile associated with traditional chemical drugs has created substantial market opportunities for natural product-based antidepressants, laying the foundation for their clinical application and market promotion.